XRTX
XORTX Therapeutics Inc. (NASDAQ)
Healthcare — Biotechnology
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Price History
Fundamentals
| Market Cap | $3.67M |
| P/E Ratio (TTM) | - |
| Forward P/E | 2.64 |
| EPS (TTM) | $-2.45 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -137.44% |
| Debt/Equity | 1.17 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 32.6 |
| Beta | 0.15 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.05 |
| 52-Week Low | $1.73 |
| 50-Day Avg | $2.41 |
| 200-Day Avg | $2.78 |
| Avg Volume | $1.28M |
| Volume | 250 |
Performance Analysis
NEUTRALXRTX presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:38 UTC
Back to Screener Export Report